Marker Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Marker Therapeutics, Inc. will hold its Annual Meeting on May 1, 2026, seeking stockholder approval for a significant increase in authorized common stock and executive compensation.
NASDAQ
DEFA14A: Marker Therapeutics Sets Date for 2025 Annual Meeting, Outlines Proposals for Shareholder Vote
Marker Therapeutics announces its 2025 Annual Meeting to be held virtually on June 6, 2025, with key proposals including the election of directors, executive compensation approval, and ratification of the company's independent auditor.
NASDAQ
Marker Therapeutics announces its Annual Meeting of Stockholders to be held virtually on June 6, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
Marker Therapeutics is holding a special meeting on March 21, 2025, to seek shareholder approval for the issuance of shares upon the exercise of private placement and pre-funded warrants.
NASDAQ
Marker Therapeutics is holding a special meeting to seek stockholder approval for the issuance of shares upon the exercise of warrants, aiming to comply with Nasdaq listing rules and secure funding for its clinical programs.
NASDAQ
Marker Therapeutics announces its annual meeting of stockholders to be held virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.